CL2009000765A1 - Composicion farmaceutica oral de sulfato de hidrogeno de 6-(4-bromo-2-cloro-fenilamino)-7-fluoro-3-metil-3h-benzoimidazol-5-acido carboxilico (2-hidroxi-etoxi)-amida en matriz portadora de succinato de d-alfa-tocoferil polietilenglicol 1000, gliceridos poliglicolizados y/o polietilenglicoles; proceso de preparacion, uso en cancer. - Google Patents

Composicion farmaceutica oral de sulfato de hidrogeno de 6-(4-bromo-2-cloro-fenilamino)-7-fluoro-3-metil-3h-benzoimidazol-5-acido carboxilico (2-hidroxi-etoxi)-amida en matriz portadora de succinato de d-alfa-tocoferil polietilenglicol 1000, gliceridos poliglicolizados y/o polietilenglicoles; proceso de preparacion, uso en cancer.

Info

Publication number
CL2009000765A1
CL2009000765A1 CL2009000765A CL2009000765A CL2009000765A1 CL 2009000765 A1 CL2009000765 A1 CL 2009000765A1 CL 2009000765 A CL2009000765 A CL 2009000765A CL 2009000765 A CL2009000765 A CL 2009000765A CL 2009000765 A1 CL2009000765 A1 CL 2009000765A1
Authority
CL
Chile
Prior art keywords
phenylamino
bromo
fluoro
ethoxy
chloro
Prior art date
Application number
CL2009000765A
Other languages
English (en)
Inventor
Nicola Frances Bateman
Paul Richard Gellert
Kathryn Jane Hill
Original Assignee
Array Biopharma Inc
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40792932&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2009000765(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Array Biopharma Inc, Astrazeneca Ab filed Critical Array Biopharma Inc
Publication of CL2009000765A1 publication Critical patent/CL2009000765A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Composición farmacéutica que comprende a una sal de sulfatode hidrogeno de 6-(4-bromo-2-cloro-fenilamino)-7-fluoro-3-metil-3h-benzoimidazo-5-acido carboxilico (2-hidroxi-etoxi)-amida y una matriz portadora con uno o mas portadores, proceso para prepararla y su uso para el tratamiento del cáncer.
CL2009000765A 2008-03-28 2009-03-27 Composicion farmaceutica oral de sulfato de hidrogeno de 6-(4-bromo-2-cloro-fenilamino)-7-fluoro-3-metil-3h-benzoimidazol-5-acido carboxilico (2-hidroxi-etoxi)-amida en matriz portadora de succinato de d-alfa-tocoferil polietilenglicol 1000, gliceridos poliglicolizados y/o polietilenglicoles; proceso de preparacion, uso en cancer. CL2009000765A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US4037208P 2008-03-28 2008-03-28

Publications (1)

Publication Number Publication Date
CL2009000765A1 true CL2009000765A1 (es) 2011-02-11

Family

ID=40792932

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2009000765A CL2009000765A1 (es) 2008-03-28 2009-03-27 Composicion farmaceutica oral de sulfato de hidrogeno de 6-(4-bromo-2-cloro-fenilamino)-7-fluoro-3-metil-3h-benzoimidazol-5-acido carboxilico (2-hidroxi-etoxi)-amida en matriz portadora de succinato de d-alfa-tocoferil polietilenglicol 1000, gliceridos poliglicolizados y/o polietilenglicoles; proceso de preparacion, uso en cancer.

Country Status (31)

Country Link
US (10) US20090246274A1 (es)
EP (1) EP2271321B1 (es)
JP (2) JP5547710B2 (es)
KR (1) KR101650958B1 (es)
CN (1) CN102046156B (es)
AR (2) AR071100A1 (es)
AU (1) AU2009229204B2 (es)
BR (1) BRPI0909267B8 (es)
CA (1) CA2718653C (es)
CL (1) CL2009000765A1 (es)
CO (1) CO6311068A2 (es)
CY (1) CY1113279T1 (es)
DK (1) DK2271321T3 (es)
EC (1) ECSP10010578A (es)
ES (1) ES2387942T3 (es)
HK (2) HK1149476A1 (es)
HR (1) HRP20120657T1 (es)
IL (1) IL208206A0 (es)
MX (1) MX2010010671A (es)
MY (1) MY157492A (es)
NZ (1) NZ588849A (es)
PE (1) PE20091755A1 (es)
PL (1) PL2271321T3 (es)
PT (1) PT2271321E (es)
RS (1) RS52409B (es)
SA (1) SA109300195B1 (es)
TW (1) TWI433840B (es)
UA (1) UA101654C2 (es)
UY (1) UY31737A (es)
WO (1) WO2009118562A1 (es)
ZA (1) ZA201006766B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI405756B (zh) 2005-12-21 2013-08-21 Array Biopharma Inc 新穎硫酸氫鹽
SA109300195B1 (ar) 2008-03-28 2013-04-20 Astrazeneca Ab تركيبة صيدلانية جديدة مضادة للسرطان
MD20150043A2 (ro) 2012-10-02 2015-08-31 Epitherapeutics Aps Inhibitori ai histon-demetilazelor
PE20151667A1 (es) 2013-02-27 2015-11-27 Epitherapeutics Aps Inhibidores de histona desmetilasas
EP3126345A1 (en) 2014-03-31 2017-02-08 Gilead Sciences, Inc. Inhibitors of histone demethylases
SG11201701182VA (en) 2014-08-27 2017-03-30 Gilead Sciences Inc Compounds and methods for inhibiting histone demethylases

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6022852A (en) 1993-10-22 2000-02-08 Hexal Ag Pharmaceutical composition containing cyclosporin A
PL179608B1 (pl) 1994-04-07 2000-10-31 Smithkline Beecham Plc Samoemulgujacy, doustny srodek farmaceutyczny do leczenia malari i dozylny srodek farmaceutyczny do leczenia malarii PL PL
CA2221145A1 (en) 1995-05-19 1996-11-21 Abbott Laboratories Self-emulsifying formulations of lipophilic drugs
BE1009856A5 (fr) 1995-07-14 1997-10-07 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule.
MY126358A (en) * 1996-03-22 2006-09-29 Glaxo Group Ltd Compositions comprising vx478 and a water soluble tocopherol derivative such as vitamin e-tpgs
US5891469A (en) 1997-04-02 1999-04-06 Pharmos Corporation Solid Coprecipitates for enhanced bioavailability of lipophilic substances
EP0988046B1 (en) 1997-01-30 2004-09-15 Novartis AG Oil-free pharmaceutical compositions containing cyclosporin a
US5891845A (en) * 1997-11-21 1999-04-06 Fuisz Technologies Ltd. Drug delivery systems utilizing liquid crystal structures
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US20030104048A1 (en) 1999-02-26 2003-06-05 Lipocine, Inc. Pharmaceutical dosage forms for highly hydrophilic materials
US6372251B2 (en) 1999-06-11 2002-04-16 Abbott Laboratories Formulations comprising lipid-regulating agents
US20030236236A1 (en) 1999-06-30 2003-12-25 Feng-Jing Chen Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
WO2004026235A2 (en) 2002-09-20 2004-04-01 Transform Pharmaceuticals, Inc. Pharmaceutical compositions with improved dissolution
CN101486682B (zh) 2002-03-13 2013-08-14 阵列生物制药公司 作为mek抑制剂的n3烷基化苯并咪唑衍生物
CN100360117C (zh) * 2002-06-21 2008-01-09 转化医药公司 具有提高的溶出度的药物组合物
US20040127551A1 (en) 2002-12-27 2004-07-01 Kai Zhang Taxane-based compositions and methods of use
AR046811A1 (es) * 2003-09-02 2005-12-28 Imran Ahmed Formas de dosificacion oral de ziprasidona de liberacion sostenida
US20050096365A1 (en) 2003-11-03 2005-05-05 David Fikstad Pharmaceutical compositions with synchronized solubilizer release
US20060003002A1 (en) 2003-11-03 2006-01-05 Lipocine, Inc. Pharmaceutical compositions with synchronized solubilizer release
AR046773A1 (es) 2003-12-23 2005-12-21 Novartis Ag Formulaciones farmaceuticas de bisfosfonatos
EP1713442A1 (en) 2004-01-30 2006-10-25 Pfizer Italia S.r.l. Semisolid matrix pharmaceutical formulations
KR20050104152A (ko) * 2004-04-28 2005-11-02 최승호 경구용 약물의 흡수를 증진하는 약제학적 조성물
WO2006138431A2 (en) 2005-06-16 2006-12-28 Eastman Chemical Company Methods and pharmaceutical formulations for increasing bioavailability
TWI405756B (zh) 2005-12-21 2013-08-21 Array Biopharma Inc 新穎硫酸氫鹽
US9561178B2 (en) 2006-07-25 2017-02-07 Allergan, Inc. Cyclosporin compositions
EP2268274B1 (en) 2008-03-20 2012-05-16 Virun, Inc. Vitamin e derivatives and their uses
SA109300195B1 (ar) 2008-03-28 2013-04-20 Astrazeneca Ab تركيبة صيدلانية جديدة مضادة للسرطان

Also Published As

Publication number Publication date
US20130195971A1 (en) 2013-08-01
BRPI0909267B8 (pt) 2021-05-25
ES2387942T3 (es) 2012-10-04
US20220087982A1 (en) 2022-03-24
CN102046156A (zh) 2011-05-04
US20090246274A1 (en) 2009-10-01
BRPI0909267A2 (pt) 2017-05-30
CN102046156B (zh) 2014-12-17
US20240041835A1 (en) 2024-02-08
NZ588849A (en) 2012-06-29
AU2009229204B2 (en) 2012-05-24
US20200179344A1 (en) 2020-06-11
SA109300195B1 (ar) 2013-04-20
CO6311068A2 (es) 2011-08-22
DK2271321T3 (da) 2012-08-27
RU2010143906A (ru) 2012-05-10
JP2014114320A (ja) 2014-06-26
US11813246B2 (en) 2023-11-14
PT2271321E (pt) 2012-08-16
UY31737A (es) 2009-11-10
WO2009118562A1 (en) 2009-10-01
US20170056375A1 (en) 2017-03-02
US20120114750A1 (en) 2012-05-10
JP5547710B2 (ja) 2014-07-16
ECSP10010578A (es) 2010-11-30
EP2271321B1 (en) 2012-06-13
HRP20120657T1 (hr) 2012-09-30
US20190030004A1 (en) 2019-01-31
JP2011515455A (ja) 2011-05-19
IL208206A0 (en) 2010-12-30
HK1149476A1 (en) 2011-10-07
AR071100A1 (es) 2010-05-26
UA101654C2 (uk) 2013-04-25
KR101650958B1 (ko) 2016-08-24
CA2718653C (en) 2016-02-09
TW200946511A (en) 2009-11-16
US20160030574A1 (en) 2016-02-04
HK1156844A1 (en) 2012-06-22
BRPI0909267B1 (pt) 2020-07-07
CY1113279T1 (el) 2016-04-13
KR20110005246A (ko) 2011-01-17
US20240041834A1 (en) 2024-02-08
CA2718653A1 (en) 2009-10-01
PL2271321T3 (pl) 2013-03-29
MY157492A (en) 2016-06-15
MX2010010671A (es) 2011-06-20
RS52409B (en) 2013-02-28
PE20091755A1 (es) 2009-12-13
RU2491920C2 (ru) 2013-09-10
AR116001A2 (es) 2021-03-25
EP2271321A1 (en) 2011-01-12
ZA201006766B (en) 2011-05-25
TWI433840B (zh) 2014-04-11
AU2009229204A1 (en) 2009-10-01

Similar Documents

Publication Publication Date Title
CL2009000765A1 (es) Composicion farmaceutica oral de sulfato de hidrogeno de 6-(4-bromo-2-cloro-fenilamino)-7-fluoro-3-metil-3h-benzoimidazol-5-acido carboxilico (2-hidroxi-etoxi)-amida en matriz portadora de succinato de d-alfa-tocoferil polietilenglicol 1000, gliceridos poliglicolizados y/o polietilenglicoles; proceso de preparacion, uso en cancer.
UY31215A1 (es) Compuestos de morfolino pirimidina, procesos para su preparacion, composiciones farmacéuticas conteniéndolos y su uso en terapia.
CL2009000816A1 (es) Metodos para modificar una estructura especifica asociada a una actividad biologica; ysu uso en el tratamiento de enfermedades y sintomas como son autoinmune, oculares, snc, cancer, entre otras.
CL2011003350A1 (es) Compuestos derivados de heterociclo nitrogenados, moduladores pkm2; composicion farmaceutica que los comprende; y su uso en el tratamiento del cancer.
NI201100082A (es) Compuestos de isoindolina para uso en el tratamiento de cáncer.
CL2007001435A1 (es) Compuestos derivados de fenilalanina; proceso de prepatacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto como inhibidores de integrina para el tratamiento del cancer.
CO6290656A2 (es) Derivados heterociclicos de urea y metodos de uso de los mismos -211
UY30819A1 (es) Derivados de pirazol, composiciones farmacéuticas conteniéndolos, procesos de preparacion y aplicaciones
UY30759A1 (es) Compuestos quimicos
CO6390097A2 (es) Formulaciones para el cuidado oral que incrementa la cantidad de zinc soluble
ECSP088974A (es) Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3)
BR112012011317A2 (pt) antagonistas espiro-oxindóis de mdm2
SV2011003855A (es) Heteroarilos sustituidos
UY32158A (es) Derivados heterociclicos y metodos de uso de los mismos
AR059957A1 (es) DERIVADOS DE ESPIROINDOLINONA, MÉTODOS PARA SU PREPARACIoN, UNA COMPOSICIoN FARMACÉUTICA QUE LOS CONTIENE Y SU USO EN LA FABRICACIoN DE MEDICAMENTOS PARA EL TRATAMIENTO DEL CÁNCER.
CL2012001366A1 (es) Compuestos derivados de carboxamida n-((2-morfolino-5-ariltiazol-4-il)metil), moduladores de receptores nicotinicos alfa 7; composicion farmaceutica; proceso para prepararla; combinacion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer, demencia, esquizofrenia, enfermedad de parkinson, entre otras.
CL2008001297A1 (es) N-[(1s)-1-(5-fluoropirim idin-2-i1 )etil]-3-(5-isopropoxi-1 h-pirazol-3-il )-3h-imidazo[4,5-b]piridin-5amina o una sal farmacéuticamente aceptabie del mismo; composición farmacéutica que lo comprende; y su uso en el tratamiento del cáncer.
CL2008001123A1 (es) Compuestos derivados de acido lipoico; formulacion farmaceutica que lo comprende; y uso en el tratamiento del cancer.
UY31141A1 (es) Compuestos de piperidina y sus usos
ECSP11011558A (es) Nuevos compuestos químicos.
UY31383A1 (es) N-aroil-n??-(6-(opcionalmente sustituido) alquilsulfonibenzotiazol-2-il)ureas
UY32674A (es) Derivados heterociclicos de la urea y sus metodos de empleo
CL2008002826A1 (es) Compuestos derivados de pirimidina alquiltio sustituidas, antagonista crth2; composicion farmaceutica que comprende a dicho compuestos; y uso para tratar una enfermedad alergica, asma, dermatitis atopica, psoriasis, colitis ulcerantes, sinusitis, leucemia basofilica, entre otras.
UY32856A (es) Derivados heterocíclicos de urea y métodos de uso de los mismos
CL2012003265A1 (es) Polisacarido de semillas de tamarindo para usarse en el tratamiento de enfermedades infecciosas; composicion farmacéutica y/o dermocosmética antiinflamatoria que contiene dicho polisacárido; uso de un polisacárido de semilla de tamarindo.